[The significance of fenofibrate in the therapy of atherogenic dyslipoproteinaemia].
There are accepted the lipid levels goals in all world, which are needed to achievement in primary and secondary prevention. Despite efficacy of current standards of care (including achievement of LDL-C, blood pressure and blood sugar goals), patients with atherogenic dyslipidemia (DLP) (high TG levels, low HDL-C, high apolipoprotein B and small dense LDL-particles), which is common in patients with diabetes melitus (DM), metabolic syndrome or cardiovascular diseases (KVD), remain exposed to a high residual risk of major cardiovascular events and microvascular complications. Statin therapy does not adequately address vascular risk asociated with elevated triglycerides (TG) and low HDL-C levels. As ACCORD lipid trial last time shows, the addition of lipid-modifying activity of fenofibrate to statin therapy benefited only certain subgroups of patients at increased cardiometabolic risk.
Kucera
M
M
II. Interná klinika Lekárskej fakulty UKa FNsP Bratislava, Slovenská republika. marekucera@gmail.com
Oravec
S
S
Ocadlík
I
I
D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy*; D011345:Fenofibrate / Q000627:therapeutic use*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008077:Lipoproteins, LDL / Q000097:blood
D000960:Hypolipidemic Agents; D008077:Lipoproteins, LDL; D011345:Fenofibrate